Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00534677
Recruitment Status : Completed
First Posted : September 26, 2007
Last Update Posted : December 5, 2007
Sponsor:
Information provided by:
Aga Khan University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Terlipressin and Octreotide are two common agents used as adjuvants in the management of variceal bleeding. Both agents have been claimed equivalent to endoscopic therapy in randomized studies. There are no head to head clinical trials of these two agents available in the literature. We aimed to compare the efficacy and safety of Terlipressin and Octreotide in combination with Endoscopic Variceal band Ligation (EVL)in patients presenting with Esophageal Variceal Bleed (EVB).

Condition or disease Intervention/treatment Phase
Portal Hypertension Cirrhosis Hematemesis Melena Drug: Terlipressin Drug: Octreotide Phase 4

Detailed Description:

The effectiveness of combining Endoscopic treatment with Octreotide or Terlipressin has not been prospectively studied in esophageal variceal hemorrhage (EVH).

This prospective, randomized clinical trial will help us in better patient management more efficiently and cost effectively.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices
Study Start Date : May 2004
Actual Study Completion Date : July 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding Safety

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: A Drug: Terlipressin
2 mg stat & then 1 mg q6h iv and Placebo of Octreotide
Other Name: Novapresin
Active Comparator: B Drug: Octreotide
Octreotide 50mcg/hr infusion & a placebo of Terlipressin
Other Name: sandostatin


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety & Efficacy [ Time Frame: 5 days ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All cirrhotic patients with upper GI bleed secondary to esophageal varices of 18 years or more of age

Exclusion Criteria:

  • Ulcerative esophagitis,
  • Mallory Weiss tear,
  • Bleeding gastric or duodenal ulcers,
  • Bleeding from gastric varices or portal hypertensive gastropathy and
  • Upper GI bleed as a result of thrombocytopenia or bleeding diathesis.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00534677


Locations
Layout table for location information
Pakistan
The Aga Khan University Hospital
Karachi, Sindh, Pakistan, 74800
Sponsors and Collaborators
Aga Khan University
Investigators
Layout table for investigator information
Principal Investigator: Shahab Abid, FCPS, FACG The Aga Khan University
Study Director: Wasim Jafri, FRCP, FACG The Aga Khan University
Study Director: Saeed S Hamid, FRCP, FACG The Aga Khan University
Study Director: Salih Mohammad, FCPS; MACG The Aga Khan University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Dr. Shahab Abid, The Aga Khan University
ClinicalTrials.gov Identifier: NCT00534677    
Other Study ID Numbers: 297-Med/ERC-04
First Posted: September 26, 2007    Key Record Dates
Last Update Posted: December 5, 2007
Last Verified: September 2007
Keywords provided by Aga Khan University:
Variceal bleed
Cirrhosis
Vasoactive agents
 Terlipressin
Octreotide
Safety & Efficacy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Portal
Hematemesis
Fibrosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Gastrointestinal Hemorrhage
Gastrointestinal Diseases
Hemorrhage
 Vomiting
Signs and Symptoms, Digestive
Octreotide
Terlipressin
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Antihypertensive Agents
Vasoconstrictor Agents